Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Greed Is Good who wrote (219)	1/30/1998 10:03:00 AM
From: Harry D. Kramer	Respond to of 1510

No one cares about IMNR being short the estimate by 1 cent in the 4th quarter. It's the R&D pipeline that matters and that is what drives the stock price. With all the news in the RA (CYPB, CNTO, IMNX, ...) and AIDS vaccine (new NIAID studies, etc.) area lately, some shareholders obviously got the impression that potential competition for IMNR pipeline products may become a problem over the long-term. Insider selling by J.B.Glavin didn't help, either. Harry

To: Greed Is Good who wrote (219)	1/30/1998 4:44:00 PM
From: Manny Gugliuzza	Read Replies (2) \| Respond to of 1510

i think harry is right. public perception of the inside sales drags heavy as he and i have posted before. since it occurs with some regularity, the volume would be more important and if others were to follow. and that rarely happens down here. right now i am focusing on the patterns forming rated to previous moves after these sales,the 50 day moving average, clearing the 13.25 close later, and eventual break out with the approval of remune by the FDA. ar.